The IL3 Knockout TE1 Polyclonal Cells product consists of a polyclonal population of human esophageal squamous cell carcinoma TE1 cells that have been genetically modified via CRISPR/Cas9-mediated gene disruption to eliminate interleukin-3 (IL-3) expression. These polyclonal knockout cells provide a loss-of-function model to study IL-3 signaling in a cancer cell line context, without selection of a single clonal isolate. The heterogeneous pool captures a range of edited alleles, enabling functional interrogation of IL-3-dependent pathways in a physiologically relevant adherent epithelial cancer model.
The TE1 cell line is a well-characterized model of human esophageal squamous cell carcinoma, widely employed in oncology studies to investigate tumorigenesis, drug response, and signaling mechanisms. Derived from a primary esophageal squamous cell carcinoma, TE1 cells maintain epithelial morphology and retain key signaling pathways relevant to esophageal cancer biology, including those influenced by inflammatory cytokines. The use of TE1 as the host cell line allows dissection of IL-3/IL3RA/CSF2RB signaling in a non-hematopoietic, carcinoma background, where autocrine and paracrine cytokine networks may contribute to tumor progression.
The IL3 gene product, interleukin-3, is a hematopoietic cytokine that binds a heterodimeric receptor composed of IL3RA (CD123) and CSF2RB, activating JAK2 and leading to phosphorylation of STAT5A and STAT5B, which transcriptionally regulate BCL2L1, CCND1, and MYC. Parallel signaling via SHC1/GAB2 stimulates the RAS-RAF-MAPK1/3 cascade, and direct PI3K recruitment activates AKT-MTOR. Upstream regulators include T-cell receptor signals and NFAT; downstream targets encompass JAK2, STAT5A/B, PIK3CA, AKT, and MAPK1/3. The receptor complex interacts with key signal transducers such as SHC1, GRB2, SOS1, PTPN11, PI3K, and AKT.
Although IL-3 primarily governs hematopoiesis, its receptor components, especially IL3RA, can be aberrantly expressed in solid tumors such as esophageal squamous cell carcinoma. In the TE1 background, knockout of IL3 disrupts potential autocrine or paracrine IL-3 signaling, dampening the JAK2/STAT5, RAS/MAPK, and PI3K/AKT pathways. This loss-of-function model enables dissection of cytokine-driven oncogenic processes and assessment of targeted therapies in esophageal cancer.
Researchers can use this polyclonal knockout pool to screen JAK/STAT pathway inhibitors, explore IL-3’s role in tumor cell survival and apoptosis, and model cytokine interactions in the tumor microenvironment. Typical experiments include western blot for phospho-STAT5, RT-qPCR for downstream targets (BCL2L1, CCND1), flow cytometry for CD123, cell proliferation (MTS/MTT) and apoptosis (Annexin V/PI) assays, phospho-kinase arrays, and cytokine profiling. These cells are also suitable for migration studies and drug sensitivity testing with JAK inhibitors. For further information or technical support, please contact Ascent Research.
